Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.
Our company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with cancer and other serious diseases.
Our novel approach to cancer treatment involves targeting the export of specific proteins in a cancer cell’s nucleus with SINE technology (Selective Inhibition of Nuclear Export).
Our primary focus is on developing novel drugs which we hope will help treat patients with certain blood cancers or solid tumor malignancies.
We seek to foster scientific creativity with pioneering technologies and developmental approaches within an innovative culture that will accelerate first-in-class small molecule modulators of nuclear transport into effective therapeutics for life-threatening conditions.
At Karyopharm, we support a culture of innovation, courage, urgency, resiliency and energy with our employees and collaborators. Integrity and respect are core to our success.
Karyopharm at a Glance
10+ years of advancing Research and Development in cancer therapeutics and nuclear export dysregulation
- 1 product approved by the FDA, EC, Medicines and Healthcare products Regulatory Agency, and the Israeli Ministry of Health, and commercially available in the US, EU, UK and Israel.
- 4 unique drug candidates in clinical development
Management team with extensive experience developing and commercializing
Headquartered in Massachusetts with presence in Germany and Israel